World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
112
Citations
58518
World Ranking
336
National Ranking
23

Medicine

D-Index
116
Citations
66586
World Ranking
4283
National Ranking
421

J. Carl Barrett publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where J. Carl Barrett sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 450 publications — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

J. Carl Barrett D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where J. Carl Barrett sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 112 D-Index — 89th percentile

89% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Overview

J. Carl Barrett is affiliated with AstraZeneca in the United Kingdom and has contributed extensively to the fields of medicine, biochemistry, genetics, and molecular biology. Their research spans multiple subfields including molecular biology, oncology, cardiology and cardiovascular medicine, radiology, nuclear medicine and imaging, as well as pulmonary and respiratory medicine. Barrett's work encompasses a range of topics predominantly focused on cancer research and molecular diagnostics.

The scientist's research areas include:

  • HER2/EGFR in Cancer Research
  • Advanced Biosensing Techniques and Applications
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Genomics and Diagnostics
  • BRCA gene mutations in cancer
  • DNA Repair Mechanisms
  • Cell Adhesion Molecules Research

Barrett's publication record features papers in several notable scientific venues. Frequent publication outlets include:

  • Cancer Research
  • PLOS Digital Health
  • Scientific Reports
  • Molecular Oncology
  • Journal of Visualized Experiments

Among recent publications are:

  • Abstract PD6-01: Novel approach to HER2 quantification: Digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients, 2021, Cancer Research
  • HER2 quantitative continuous scoring for accurate patient selection in HER2 negative trastuzumab deruxtecan treated breast cancer, 2024, Scientific Reports
  • Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection, 2021, Molecular Oncology
  • Insights from a single centre implementation of a digitally-enabled atrial fibrillation virtual ward, 2024, PLOS Digital Health
  • Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis, 2021, Journal of Visualized Experiments

Barrett frequently collaborates with a consistent group of co-authors, indicating interdisciplinary teamwork in their research efforts. These co-authors include Hadassah Sade, Ansh Kapil, Sadia Khan, Susanne Haneder, and Ana Hidalgo-Sastre.

Best Publications

  • A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1

    Yoshio Miki;Jeff Swensen;Donna Shattuck-Eidens;P. Andrew Futreal

  • Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability

    Asad Umar;C. Richard Boland;Jonathan P. Terdiman;Sapna Syngal

  • Genomic Instability and Aging-like Phenotype in the Absence of Mammalian SIRT6

    Raul Mostoslavsky;Katrin F. Chua;Katrin F. Chua;David B. Lombard;Wendy W. Pang

  • Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins.

    Eriko Michishita;Jean Y. Park;Jenna M. Burneskis;J. Carl Barrett

  • Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: A preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

    Jonathan Ledermann;Philipp Harter;Charlie Gourley;Michael Friedlander

  • Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

    Kenneth S Thress;Cloud P Paweletz;Enriqueta Felip;Byoung Chul Cho

  • GoMiner: a resource for biological interpretation of genomic and proteomic data

    Barry R Zeeberg;Weimin Feng;Geoffrey Wang;May D Wang

  • SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin

    Eriko Michishita;Ronald A. McCord;Elisabeth Berber;Mitomu Kioi

  • Microarrays and toxicology: the advent of toxicogenomics.

    Emile F. Nuwaysir;Michael Bittner;Jeffrey Trent;J. Carl Barrett

  • Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks

    Olga A. Sedelnikova;Izumi Horikawa;Drazen B. Zimonjic;Nicholas C. Popescu

  • Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

    Geoffrey R. Oxnard;Kenneth S. Thress;Ryan S. Alden;Rachael Lawrance

  • HIF‐1α induces cell cycle arrest by functionally counteracting Myc

    Minori Koshiji;Yukio Kageyama;Erin A Pete;Izumi Horikawa

  • VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

    Zhongwu Lai;Aleksandra Markovets;Miika Ahdesmaki;Brad Chapman

  • Calorie Restriction, Aging, and Cancer Prevention: Mechanisms of Action and Applicability to Humans*

    Stephen D. Hursting;Jackie A. Lavigne;David Berrigan;Susan N. Perkins

  • Clinical proteomics: translating benchside promise into bedside reality

    Emanuel F. Petricoin;Kathryn C. Zoon;Elise C. Kohn;J. Carl Barrett

  • Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

    Amit M Oza;David Cibula;Ana Oaknin Benzaquen;Christopher Poole

  • Gene expression analysis reveals chemical-specific profiles.

    Hisham K. Hamadeh;Pierre R. Bushel;Supriya Jayadev;Karla Martin

  • Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.

    Kristin K. Zorn;Tomas Bonome;Lisa Gangi;Gadisetti V.R. Chandramouli

  • EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

    Kenneth S. Thress;Roz Brant;T. Hedley Carr;Simon Dearden

  • Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer.

    Suresh S. Ramalingam;James C.-H. Yang;Chee Khoon Lee;Takayasu Kurata

Frequent Co-Authors

Mitsuo Oshimura
Mitsuo Oshimura Tottori University
Stephen D. Hursting
Stephen D. Hursting University of North Carolina at Chapel Hill
Cynthia A. Afshari
Cynthia A. Afshari Janssen (United States)
Andrew Berchuck
Andrew Berchuck Duke University
Vladimir Larionov
Vladimir Larionov National Institutes of Health
John T. Isaacs
John T. Isaacs Johns Hopkins University
John A. McLachlan
John A. McLachlan Tulane University
P. Andrew Futreal
P. Andrew Futreal The University of Texas MD Anderson Cancer Center
Jonathan A. Ledermann
Jonathan A. Ledermann University College London
Paul Nettesheim
Paul Nettesheim National Institutes of Health

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Studying Molecular Biology in the USA opens doors to a diverse range of health science and medical careers. For students interested in expanding their impact or pursuing patient care, many transition to advanced nursing pathways. Understanding how long to become nurse practitioner is important for setting realistic goals and planning your educational journey.

There are several fast-track options for those with previous credentials or a related science background. For registered nurses seeking further qualification, completing a rn to bsn in 6 months program is a popular choice, offering an accelerated route to broaden career opportunities.

Graduates of associate degree programs can consider asn to fnp programs that bridge the gap to advanced practice and leadership roles. Additionally, individuals from non-nursing backgrounds can access direct entry msn programs for non nurses online to quickly jumpstart a new career in healthcare.

Exploring these online degrees and pathways allows Molecular Biology graduates to leverage their scientific knowledge in clinical, research, and allied health environments, often with the flexibility to study while working.

Best Scientists Citing J. Carl Barrett

Trending Scientists

Recently Published Articles